Price T Rowe Associates Inc. MD Has $22.19 Million Stock Holdings in Bicycle Therapeutics plc (NASDAQ:BCYC)

Price T Rowe Associates Inc. MD reduced its stake in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 8.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,585,127 shares of the company's stock after selling 136,913 shares during the quarter. Price T Rowe Associates Inc. MD owned about 2.30% of Bicycle Therapeutics worth $22,192,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of BCYC. Barclays PLC lifted its position in Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock valued at $37,000 after purchasing an additional 2,345 shares during the period. Avior Wealth Management LLC acquired a new stake in shares of Bicycle Therapeutics in the 4th quarter valued at approximately $57,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Bicycle Therapeutics by 30.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock valued at $131,000 after buying an additional 2,191 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock valued at $191,000 after buying an additional 1,782 shares in the last quarter. Finally, Jane Street Group LLC raised its position in Bicycle Therapeutics by 35.7% during the third quarter. Jane Street Group LLC now owns 20,180 shares of the company's stock worth $457,000 after acquiring an additional 5,310 shares in the last quarter. Institutional investors and hedge funds own 86.15% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Barclays reduced their price target on Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a report on Thursday, May 1st. Morgan Stanley set a $17.00 price target on Bicycle Therapeutics and gave the company an "equal weight" rating in a report on Monday. JMP Securities dropped their price objective on shares of Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating on the stock in a research report on Friday, May 2nd. Stephens reaffirmed an "equal weight" rating and set a $15.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. Finally, B. Riley dropped their price target on Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating for the company in a report on Friday, May 2nd. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $25.00.

Bicycle Therapeutics Price Performance

BCYC traded up $0.26 during trading on Wednesday, hitting $7.66. 178,012 shares of the stock traded hands, compared to its average volume of 395,855. The business has a 50 day moving average price of $8.59 and a 200 day moving average price of $14.13. The company has a market cap of $530.09 million, a price-to-earnings ratio of -2.37 and a beta of 1.60. Bicycle Therapeutics plc has a twelve month low of $6.10 and a twelve month high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $9.98 million during the quarter, compared to the consensus estimate of $8.67 million. On average, equities research analysts predict that Bicycle Therapeutics plc will post -3.06 earnings per share for the current year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.